Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SENT008
- Development stage
- Preclinical
- Lead developer
- Sentio BioSciences
- Modality
- Small Molecules
01
Overview
SENT008 is a preclinical-stage small molecule therapeutic candidate being developed by Sentio BioSciences for the treatment of osteoarthritis. The drug is part of the company's pipeline focused on inflammatory and degenerative diseases, utilizing a proprietary drug discovery platform to identify novel inhibitors. SENT008 is intended to address the underlying pathology of joint degeneration and the associated inflammatory environment in patients with osteoarthritis. As of the latest reports, the specific biological target and detailed mechanism of action for SENT008 have not been publicly disclosed by the sponsor.
Beyond the preview
Go deeper on SENT008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SENT008.